Extremely premature neonates who have been exposed to pre-eclampsia in utero are at high risk of developing severe respiratory distress syndrome and severe bronchopulmonary dysplasia, according to a study.
Polycystic ovary syndrome (PCOS) does not appear to significantly impair sexual function, a recent meta-analysis has shown. However, there is a need for further and stronger studies to confirm the findings.
The sodium‐glucose‐cotransporter‐2 inhibitor empagliflozin yields beneficial effects on weight anthropometric parameters and body composition—including weight, body mass index, waist and hip circumference, and total body fat—that are greater than those achieved with metformin in overweight and obese women with polycystic ovary syndrome (PCOS), a study has shown.
Infants born to mothers with polycystic ovary syndrome (PCOS) are less likely to be large for gestational age, according to data from the SCOPE* cohort study. Moreover, PCOS does not carry an increased risk of pregnancy complications in women following a healthy lifestyle.
A lifestyle intervention programme focusing on healthy habits was associated with weight loss and better disease-free survival (DFS) among early breast cancer survivors, according to the SUCCESS C* study presented at SABCS 2018.
TX-001HR, a fixed-dose combination of oestradiol and progesterone, yields clinically meaningful improvements in the frequency and/or severity vasomotor symptoms in menopausal women with a uterus, according to a study.
Adding bevacizumab to platinum-based chemotherapy significantly improves progression-free survival (PFS) in patients with recurrent ovarian cancer who were previously treated with first-line bevacizumab, according to the MITO16B - MaNGO OV2B - ENGOT OV17* study presented at ASCO 2018.